Data from the phase III PERSEUS study showed that a Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based quadruplet induction, consolidation regimen and doublet maintenance regimen showed clinical improvement in the treatment of transplant-eligible newly diagnosed multiple myeloma.
A research team at UVA Health is testing the ability of focused ultrasound to increase the immune response to immunotherapy in melanoma. UVA’s work with focused ultrasound already has led to life-changing new treatments for Parkinson’s disease and essential tremor and pushed the technology to the forefront of medical research.
